CLXPF - Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Featured in Stifel Report; Price Target Raised by C$12 Rated as Spec Buy
- CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, report observed
- Stifel also notes selecting indications with large patient pools, an understated market size, and potential for multiple synergies across development and distribution
- Report incorporates both CYB001 and CYB004 into valuation
As Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, continues to develop its multimolecule strategy, people are paying attention. A recent Stifel report raised Cybin’s price target by C$12, up from C$4 to C$15, and maintained the company’s speculative buy rating (https://ibn.fm/HLcxX).
“CYBN continues to demonstrate good progress with its preclinical activities on its novel drug programs, including CYB004, with the announcement of two chosen indications, Social Anxiety Disorder (‘SAD’) and Generalized Anxiety Disorder (‘GAD’), some of the most common...
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.